Inari Medical (NARI)
(Delayed Data from NSDQ)
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:50 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:50 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.
QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down
by Zacks Equity Research
In an increasingly challenging macro environment, QIAGEN (QGEN) surpasses the earnings and revenue outlook in the third quarter of 2023.
Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More
by Indrajit Bandyopadhyay
Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.
Zacks Industry Outlook Highlights Alcon, STERIS and Inari Medical
by Zacks Equity Research
Alcon, STERIS and Inari Medical are part of the Zacks Industry Outlook article.
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.
3 Medical Instruments Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is being affected by ongoing inflation and a tightening monetary policy. However, the rising demand for digital health offers some respite. ALC, STE and NARI are poised to brave the challenges.
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
by Zacks Equity Research
Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment.
ResMed (RMD) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.
Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.
Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip
by Zacks Equity Research
Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.
Labcorp (LH) Q3 Earnings and Revenues Beat, Margins Fall
by Zacks Equity Research
Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.
Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut
by Zacks Equity Research
The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.
Align Technology (ALGN) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Align Technology's (ALGN) Q3 fiscal 2023 performance reflects revenue growth across all regions.
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.
Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips
by Zacks Equity Research
Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.
3 Solid Stocks to Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
4 Stocks That Exhibit Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.
Wall Street Analysts See a 36.39% Upside in Inari Medical, Inc. (NARI): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 36.4% upside potential for Inari Medical, Inc. (NARI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Inari Medical, Inc. (NARI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 128.57% and 2.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Inari Medical (NARI) Stock to Your Portfolio
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.
Inari Medical (NARI) Launches New Catheters to Address VTE
by Zacks Equity Research
Inari Medical's (NARI) latest launches are expected to serve a wider patient pool by improving treatment options.